BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 192067)

  • 1. Effects of dibutyryl cyclic adenosinemonophosphate and prostaglandin E1 on platelet aggregation and shape changes.
    Wang TY; Hussey CV; Garancis JC
    Am J Clin Pathol; 1977 Apr; 67(4):362-7. PubMed ID: 192067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions.
    Minkes M; Stanford N; Chi MM; Roth GJ; Raz A; Needleman P; Majerus PW
    J Clin Invest; 1977 Mar; 59(3):449-54. PubMed ID: 190267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic AMP and platelet prostaglandin synthesis.
    Gerrard JM; Peller JD; Krick TP; White JG
    Prostaglandins; 1977 Jul; 14(1):39-50. PubMed ID: 197570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of platelet cyclic nucleotide content by PGE1 and the prostaglandin endoperoxide PGG2.
    Miller OV; Gorman RR
    J Cyclic Nucleotide Res; 1976; 2(2):79-87. PubMed ID: 177467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
    Zahavi M; Zahavi J; Kakkar VV
    Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of ADP-induced responses in human platelets by agents elevating the cyclic AMP level: comparison of aggregation and shape change.
    Steen VM; Holmsen H
    Thromb Haemost; 1984 Dec; 52(3):333-5. PubMed ID: 6099615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of prostaglandins E1 and E2 on thrombocyte form and aggregation].
    Antonikov IM; Alekseev OV; Chernukh AM
    Biull Eksp Biol Med; 1982 Apr; 93(4):11-3. PubMed ID: 6952942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human platelet secretion and aggregation induced by calcium ionophores. Inhibition by PGE1 and dibutyryl cyclic AMP.
    Feinstein MB; Fraser C
    J Gen Physiol; 1975 Nov; 66(5):561-81. PubMed ID: 172596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of pyridoxal-5-phosphate on the inhibition of platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation in human platelets.
    Zahavi M; Zahavi J; Kakkar VV
    Life Sci; 1984 Oct; 35(14):1497-503. PubMed ID: 6090838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interrelation of prostaglandin endoperoxide (prostaglandin G2) and cyclic 3',5'-adenosine monophosphate in human blood platelets.
    Salzman EW
    Biochim Biophys Acta; 1977 Aug; 499(1):48-60. PubMed ID: 196670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP.
    Haslam RJ; Davidson MM; Desjardins JV
    Biochem J; 1978 Oct; 176(1):83-95. PubMed ID: 215136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of prostaglandins, derivatives of cyclic 3':5'-AMP, theophylline, cholinergic agents and colchicine on clot retraction in dilute platelet-rich plasma and gel-separated platelet test systems.
    Moake JL; Cimo PL; Widmer K; Peterson DM; Gum JR
    Thromb Haemost; 1977 Aug; 38(2):420-8. PubMed ID: 202038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cyclic adenosine monophosphate, prostaglandin E and aggregation of blood platelets in man].
    Ardelt W
    Fortschr Med; 1977 Feb; 95(6):366-70. PubMed ID: 190100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substances that increase the cyclic AMP content prevent platelet aggregation and the concurrent release of pharmacologically active substances evoked by arachidonic acid.
    Vargaftig BB; Chignard M
    Agents Actions; 1975 May; 5(2):137-44. PubMed ID: 51579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation between the inhibition of aggregation and the concentration of cAMP in human and rat platelets.
    Michel H; Caen JP; Born GV; Miller R; D'Auriac GA; Meyer P
    Br J Haematol; 1976 May; 33(1):27-38. PubMed ID: 178342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat.
    Ashida SI; Abiko Y
    Thromb Haemost; 1979 Apr; 41(2):436-49. PubMed ID: 224522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6-Keto-prostaglandin E1 inhibits the aggregation of human platelets.
    Wong PY; McGiff JC; Sun FF; Lee WH
    Eur J Pharmacol; 1979 Dec; 60(2-3):245-8. PubMed ID: 393526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet prostaglandin E1 hyposensitivity in schizophrenia: decrease in cyclic AMP formation and in inhibitory effects on aggregation.
    Kaiya H; Ofuji M; Nozaki M; Tsurumi K
    Psychopharmacol Bull; 1990; 26(3):381-4. PubMed ID: 2177206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of platelet responsiveness through selective phosphorylation of plasma membrane proteins.
    Apitz-Castro R; De Murciano A
    Biochim Biophys Acta; 1978 Dec; 544(3):529-39. PubMed ID: 215226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effet of prostaglandin E1 alone and in combination with theophylline or aspirin on collagen-induced platelet aggregation and on platelet nucleotides including adenosine 3':5'-cyclic monophosphate.
    Ball G; Brereton GG; Fulwood M; Ireland DM; Yates P
    Biochem J; 1970 Dec; 120(4):709-18. PubMed ID: 4322038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.